12-12-03

EXPRESS MAIL NO. EV336611740US

1	E JC	03
0	OFFE	PK OFFIG
	ATEMT &	3

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/960,264	۷.
Filing Date	September 20, 2001	
First Named Inventor	Ronald Berenson	
Art Unit	1651	
Examiner Name	L. Blaine Lankford	
Attorney Docket No.	980034.417C1	

ENCLOSURES (check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Third Supplemental Information Disclosure Statement; Forms PTO-1449 (3 Sheets) Solve Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):						
<u>Remarks</u>								
CICALATUE	DE OF ARRIVANT ATTORNEY	OD ACENT						
Individual Name Julie A. Urva Reg.No. 50,4	ter, Ph.D., Patent Agent	Customer Number 00500						
Signature	lie (state							
Date December 10), 2003							
0505	TEICATE OF TRANSMISSION	All INC						
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.								
Typed or printed name								
Signature	5. The information is required to obtain as rate is a baseful	Date:						

Inis collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

oplicant claims small entity status. See 37 CFR 1.27.

TAL AMOUNT OF PAYMENT

180.00

Complete if Known							
Application Number	09/960,264						
Filing Date	September 20, 2001						
First Named Inventor	Ronald Berenson						
Examiner Name	L. Blaine Lankford						
Art Unit	1651						
Attorney Docket No.	980034.417C1						

لر	No.		ME	THOD C	F PAYMENT					
7	M Do	ment Encl	ocod:							
	15 4	Check	Credit ca	ard	Money Order	Other				
	Deposit Account:									
	A	eposit sccount lumber	19-10	90	•					
	Deposit Account Name Seed Intellectual Property Law Group PLLC									
		Charge fee Charge an Charge fee	e(s) indicat ny additiona e(s) indicat ny deficienc	ed below Il fee(s) o ed below ies	during the pendency					
			F	EE CAL	CULATION	· · · · · · · · · · · · · · · · · · ·				
	1. BAS	SIC FILING	FEE							
	Large E		mall Entit	¥						
	Fee	Fee(\$)		ee(\$)	Fee Description	Fee				
	Code	770	Code		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Paid				
	1001	770	2001	385	Utility filing fee					
	1002	340	2002	170	Design filing fee					
	1003	530	2003	265	Plant filing fee					
	1004	770	2004	385	Reissue filing fee					
	1005	160	2005	80	Provisional filing fee					
					SUBTOTAL (1)	(\$)				
	2. EXT	RA CLAIM	FEES FC	R UTIL	ITY AND REISSU	<u>E</u>				
	Total Cla			.** = _** =	Extra fro	m Fee				
	Claims Multiple									
	Depende	Entity	Small E	atitu	<u> </u>					
	Fee	Fee	Fee	Fee						
	Code	(\$)	Code	(\$)	Fee Description	1				
	1202	18	2202	9	Claims in excess	s of 20				
	1201	86	2201	43	Independent clai	ims in excess of 3				
	1203	290	2203	145		ent claim, if not paid				
	1204	86	2204	43	** Reissue inder original paten	pendent claims over t				
	1205	18	2205	9	** Reissue claim and over origi	ns in excess of 20 inal patent				
				SUB	TOTAL (2)	\$)				
	**or nun	nber previou	sly paid, if g	reater; F	or Reissues, see abo	ve				

FEE CALCULATION (continued)								
3. ADDI								
Large Entity Small								
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid			
1051	130	2051	65	Surcharge - late filing fee or oath				
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.				
1053	130	1053	130	Non-English specification				
1812	2520	1812	2520	For filing a request for ex parte reexamination				
1804	920°	1804	920*	Requesting publication of SIR prior to Examiner action				
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action				
1251	110	2251	55	Extension for reply within first month				
1252	420	2252	210	Extension for reply within second month				
1253	950	2253	475	Extension for reply within third month				
1254	1480	2254	740	Extension for reply within fourth month				
1255	2010	2255	1005	Extension for reply within fifth month				
1401	330	2401	165	Notice of Appeal				
1402	330	2402	165	Filing a brief in support of an appeal				
1403	290	2403	145	Request for oral hearing				
1451	1510	1451	1510	Petition to institute a public use proceeding				
1452	110	2452	55	Petition to revive – unavoidable				
1453	1330	2453	665	Petition to revive – unintentional				
1501	1330	2501	665	Utility issue fee (or reissue)				
1502	480	2502	240	Design issue fee				
1503	640	2503	320	Plant issue fee				
1460	130	1460	130	Petitions to the Commissioner				
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)				
1806	180	1806	180	Submission of Information Disclosure Stmt	180			
8021	40	8021	40	Recording each patent assignment per property (times number of properties)				
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))				
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))				
1801	770	2801	385	Request for Continued Examination (RCE)				
1802	900	1802	900	Request for expedited examination of a design application				
Other fee	(specify)						
		•						
*Reduce	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 180.00							

	SUBMITTED BY	Customer Number				
Name (Print/Type)	Julie A. Urvater, Ph.D., Patent Agent	Registration No. Attorney/Agent) 50,461				
Signature	Chille Verato	Date De	ecember 10, 2003	00500		

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313, 450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXPRESS MAIL NO. EV336611740US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Ronald Berenson et al.

Application No.

09/960,264

Filed

September 20, 2001

For

SIMULTANEOUS STIMULATION AND CONCENTRATION OF

CELLS

Examiner

: L. Blaine Lankford

Art Unit

1651

Docket No.

: 980034.417C1

Date

: December 10, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

12/16/2003 JEALINAN 00000100 09960264

01 FC:1806

180.00 OP

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Julie A Prvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt Enclosures:

> Postcard Check for \$180 Transmittal Form Fee Transmittal Form (+ Copy) Forms PTO-1449 (3 Sheets) Cited References (35)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\439413

FORM PTO-1449	-	NO. EV330011/401	DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO.		APPLICATION NO.	sheet 1	01 _3_
(REV.7-80) PATENT AND TRADEMARK OFFICE			980034.417C1 09/960,264						
P FINIRD SUPPLEMENTAL				APPLICANTS		<u> </u>			
Ore	DRM.	ATION DISCLOSU	RE STATEM	ENT	Ronald Berenson et a	al.			
	. n 11	several sheets if nece	essary) `		FILING DATE		GROUP ART UNIT		
	102		September 20, 2001		1651				
*EXAMINE**		wet 2	U.S.	PATENT 1	DOCUMENTS				
*EXAMINE** INITIAL	TRADY	DOCUMENT NUMBER	DATE		NAME	CLA	ASS SUBCLASS		G DATE OPRIATE
	AA	5,443,983	08/22/95	Ochoa et	al.	435	240.2		
	AB	5,470,730	11/28/95	Greenberg	g et al.	435	172.3		
	AC	5,674,704	10/07/97	Goodwin	et al.	435	69.1		
	AD	5,804,442	09/08/98	Romet-Le	emonne et al.	435	374		
	AE	6,113,901	09/05/00	Bluestone	.	424	154.1		
	AF	6,143,297	11/07/00	Bluestone	;	424	184.1	<u> </u>	
	AG	6,129,916	10/10/00	Chang		424	179.1		
	AH	6,197,298	03/06/01	Chang		424	179.1		
	Al	6,316,257	11/13/01	Flyer et al	l.	435	372.3		
	AJ	6,355,779	03/12/02	Goodwin	et al.	530	388.23		
			FOREI	GN PATEN	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS	LATION NO
L	AK	EP 633930 B1	04/26/00	EPO					
/	AL	WO 97/05233	02/13/97	WIPO					
<i>,</i> /	AM	WO 97/05239	02/13/97	WIPO					
·	AN	WO 03/024312	03/27/03	WIPO					
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	iges, Etc.)		
	AO	Baroja, M.L.	et al., "The	Anti-T Cel	l Monoclonal Antibod	y 9.3 ((Anti-CD28) F	rovides	a
· ~		<u> </u>			d for Accessory Cells		•		
		Immobilized	Anti-CD3 a	nd Mitoger	ns," Cellular Immunolo	ogy 12	20: 205-217, 1	989.	
/	AP	Bergstresser,	P.R. et al., '	'T Cell-Me	diated Terminal Matur	ation	of Dendritic C	Cells," ii	n
ν		Dendritic Ce	ll in Fundan	nental and	Clinical Immunology,	Riccia	ardi-Castognol	i (Ed.),	
		Plenum Press	, New York	, 1997, pgs	s. 65-69.				
	AQ	Groh, V. et a	., "Stimulat	ion of T Ce	ell Autoreactivity by A	nomal	lous Expression	n of NI	CG2D
	/ -	and its MIC I	Ligands in R	heumatoid	Arthritis," Proceeding	gs of th	he National Ad	cademy	of
	Sciences 100(16): 9452-9457, Augest 5, 2003.								
EXAMINE	R				DATE CONSIDERED				
* EVANINI	2D ·	Indicate to the control of the		Contact to t		<u> </u>	1 1 1 10 1		
* EXAMINI					nformance with MPEP 609. Draw with next communication to appli		ough citation if not i	n 	

U.S. DEPARTMENT OF COMMERCE FORM PTO-1449 ATTY. DOCKET NO. APPLICATION NO. (REV.7-80) PATENT AND TRADEMARK OFFICE 980034.417C1 09/960,264 APPLICANTS ETHIRD SUPPLEMENTAL MATION DISCLOSURE STATEMENT Ronald Berenson et al. DEC 1 0 2003 (5) several sheets if necessary) FILING DATE **GROUP ART UNIT** September 20, 2001 1651 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATE INITIAL 424 93.1 2001/0031253 10/18/01 Gruenberg BA 2002/0090362 07/11/02 **Strauss** 424 93.21 BB 2002/0182730 12/05/02 Gruenberg 435 375 BC 424 144.1 2003/0039650 02/27/03 Gruenberg BD 435 7.21 2003/0134341 07/17/03 Gruenberg BE 435 372 2003/0134415 07/17/03 BF Gruenberg 144.1 2003/0170238 09/11/03 Gruenberg 424 BG 09/18/03 424 93.2 2003/0175242 Gruenberg BH 09/18/03 424 144.1 2003/0175272 Gruenberg ΒI 424 93.7 2003/0194395 10/16/03 Gruenberg et al. BJ FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER DATE COUNTRY YES NO WO 03/025158 03/27/03 **WIPO** BK WO 03/034820 05/01/03 **WIPO** BL WO 03/043643 05/30/03 **WIPO** RM WO 03/077658 09/25/03 WIPO BN OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T во Cell Responses," from The Midwinter Conference of Immunologists, January 22-25, 2000, available at www.midwconfimmunol.org/Midwinter00/sessions/lanzavecchia.html. Li, Q. et al., "Expanded Tumor-reactive CD4⁺ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation," Clinical Cancer Research 5: 461-469, February 1999. Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autologous Tumor BO Vaccines," Clinical Immunology 94(1): 64-72, January 2000. **EXAMINER** DATE CONSIDERED * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	9				ATTY. DOCKET NO.	•		ICATION NO.		
			980034.417C1 09/960,264 APPLICANTS							
	20	THIRD SUPPLEM		DAM	1	ol.				
NI ORIGA NON DISCLOSU			KE STATEM.	ENI	Ronald Berenson et	ai.	CRO	UD A DT I DOT		
		→ \	zsaiy)		FILING DATE			UP ART UNIT		
DEC	1 0 300				September 20, 2001		165) [
132			U.S.	PATENT	DOCUMENTS					
*EXAM***R 7	RATE	DOCUMENT NUMBER	DATE		NAME	CLA	.SS	SUBCLASS	FILING IF APPRO	
	CA									
	СВ			**************************************						
	сс									
	CD									
	CE					<u> </u>				
	CF									
	cg ·									
	СН									
_	СІ									
	СЛ									
ů.			FOREI	GN PATE	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY		· · · · · · · · · · · · · · · · · · ·		TRANS! YES	LATION NO
	СК									
	CL									
	СМ									
	CN									
	со					-	,			
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent F	ages, Etc.)			
-	/	Zou I-P et	al. "Tumor-	Bearing M	ice Exhibit A Progres	sive In	creas	se in Tumo	r Antic	en-
i /	CP			_	_					
\mathcal{V}		i -			iprocal Decrease in T				31VC C	ן דע
· · · · · · · · · · · · · · · · · · ·		Cell Activity	," The Journ	ial of Immi	inology 148(2): 648-6	55, Jan	uary	15, 1992.	ν,	
	cQ									
	CR									
EXAMINE	 7 D				DATE CONSIDERED					
* EXAMIN					nformance with MPEP 609. Dra	lina the	auah a	itation if not in		